This was associated with decreased activity of the m6A-modified gene encoding Tyrosine Phosphatase Shp-2 (SHP-2), inhibition of KT-mTOR and MAPK-ERK signaling pathways as well as decreased response to IL-15 and suggests that METTL3-mediated m6A promotes NK cells and can alleviate tumor progression, providing new possibilities for cancer immunotherapy in the future (53). The gene discussed is METTL3; the disease is neoplasm.